Switch theme
Sign up to access all valuation multiples
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
2016
23
LTM Revenue $9.3M
Last FY EBITDA -$36.2M
$51.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Unicycive has a last 12-month revenue (LTM) of $9.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Unicycive achieved revenue of n/a and an EBITDA of -$36.2M.
Unicycive expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Unicycive valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $7.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$36.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$31.3M | XXX | -$32.1M | XXX | XXX | XXX |
| EBIT Margin | -336% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$30.1M | XXX | -$36.7M | XXX | XXX | XXX |
| Net Margin | -323% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Unicycive's stock price is $1.
Unicycive has current market cap of $70.7M, and EV of $51.6M.
See Unicycive trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $51.6M | $70.7M | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Unicycive has market cap of $70.7M and EV of $51.6M.
Unicycive's trades at 76.4x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Unicycive's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Unicycive has a P/E ratio of -2.3x.
See valuation multiples for Unicycive and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $70.7M | XXX | $70.7M | XXX | XXX | XXX |
| EV (current) | $51.6M | XXX | $51.6M | XXX | XXX | XXX |
| EV/Revenue | 5.5x | XXX | 76.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUnicycive's last 12 month revenue growth is 1586%
Unicycive's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Unicycive's rule of 40 is -2884% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Unicycive's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Unicycive and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1586% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2884% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Unicycive acquired XXX companies to date.
Last acquisition by Unicycive was XXXXXXXX, XXXXX XXXXX XXXXXX . Unicycive acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Unicycive founded? | Unicycive was founded in 2016. |
| Where is Unicycive headquartered? | Unicycive is headquartered in United States of America. |
| How many employees does Unicycive have? | As of today, Unicycive has 23 employees. |
| Who is the CEO of Unicycive? | Unicycive's CEO is Dr. Shalabh Gupta, M.D.. |
| Is Unicycive publicy listed? | Yes, Unicycive is a public company listed on NAS. |
| What is the stock symbol of Unicycive? | Unicycive trades under UNCY ticker. |
| When did Unicycive go public? | Unicycive went public in 2021. |
| Who are competitors of Unicycive? | Similar companies to Unicycive include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Unicycive? | Unicycive's current market cap is $70.7M |
| What is the current revenue of Unicycive? | Unicycive's last 12 months revenue is $9.3M. |
| What is the current revenue growth of Unicycive? | Unicycive revenue growth (NTM/LTM) is 1586%. |
| What is the current EV/Revenue multiple of Unicycive? | Current revenue multiple of Unicycive is 5.5x. |
| Is Unicycive profitable? | Yes, Unicycive is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
